175 results
Page 2 of 9
8-K
EX-10.1
kf7mxu6 pnmv4u0
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-99.1
b77p620tmp9x9gin
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-99.1
tk2o0howvn3nqt
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
mrce xhsoo
11 Aug 22
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
7:15am
8-K
EX-10.3
gusc5fq lgizz5k
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
8-K
EX-99.1
x01 roto3ecjafm17ct
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
bzwaqvb
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.2
wn460w7vzk pcp2s
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.3
dptqesw3os3f78
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
3atj5x
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
ksv3q2qsl9w
11 May 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
gd8m6
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
EX-10.2
4wuc5gv s9tq
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
EX-10.1
xdiw8
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
424B5
73yidpc ass6
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
c1tjfsso
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
8ekgmt
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am